SKYE

Business Context and Reporting Period

Company: Skye Bioscience, Inc. (Skye)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Skye is a clinical-stage biotechnology company developing next-generation molecules to treat obesity and metabolic diseases. Its lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor. The company has not yet generated revenue and relies on capital raises to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: No revenue recognized in the current or prior periods.
• Net Loss: Net loss for the nine months ended Sept 30, 2025, increased to $41.5 million from $16.8 million in the same period in 2024. This increase is primarily due to higher R&D expenses and the absence of a $4.55 million gain from a change in legal contingency estimate recorded in 2024.
• R&D Expenses: Increased by 183% year-over-year for the nine-month period ($30.9M vs. $10.9M). The increase is driven by clinical trial costs for the nimacimab Phase 2a extension and significant contract manufacturing costs for drug substance and process optimization.
• General & Administrative (G&A): Decreased by 6% year-over-year for the nine-month period ($12.4M vs. $13.2M), attributed to lower recruiting fees and professional services, partially offset by increased investor relations costs.
• Cash Position: Cash and cash equivalents decreased from $68.4 million at year-end 2024 to $18.4 million at Sept 30, 2025. This reduction reflects operating cash burn of $33.3 million and investing outflows of $16.7 million (primarily short-term investments).

Guidance, Outlook, and Risks

Clinical Development & Outlook

• Phase 2a Results: In October 2025, Skye reported that nimacimab monotherapy did not meet the primary endpoint for weight loss vs. placebo. However, the combination of nimacimab and semaglutide showed clinically meaningful weight loss (-13.2% vs. -10.25% for semaglutide alone) with a favorable safety profile.
• Next Steps: Management implemented a cost reduction plan. The company is proceeding with a Phase 2a extension study (enrollment complete, 43 patients) and expects to report data in Q1 2026. Future studies may evaluate higher doses of nimacimab.
• Liquidity Runway: Management believes current cash and short-term investments ($35.3M) are sufficient to fund operations for at least 12 months from the filing date. Additional funding will be required for subsequent clinical studies.

Risks and Contingencies

• Legal Proceedings: The company is involved in the "Cunning Lawsuit" (Wendy Cunning vs. Skye Bioscience). A previous judgment was vacated by the Ninth Circuit, and a new trial is scheduled for February 2026. The company has accrued $2.05 million for this contingency.
• Capital Requirements: The company has no revenue and expects to incur significant losses. Failure to raise additional capital could materially impact operations.
• Macroeconomic Factors: Risks include supply chain disruptions, inflation, and the impact of the U.S. federal government shutdown (ongoing since Oct 1, 2025).

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $35.3M liquidity position against the $33.3M operating cash burn in the first nine months of 2025.
• Legal Exposure: Monitor the status of the Cunning Lawsuit new trial scheduled for February 2026 and potential changes to the $2.05M accrued liability.
• Clinical Data: Await Q1 2026 data from the Phase 2a extension study to validate the efficacy of higher doses or combination therapies.
• Financing Needs: Assess the timeline and terms for potential future equity or debt financings required to fund the next phase of nimacimab development.
• Stock-Based Compensation: Review the $6.15M in stock-based compensation expense for the nine-month period and its impact on future dilution.